🔎 Trials Near Me

Home › Diffuse Scleroderma › California

Diffuse Scleroderma clinical trials in California

9 studies for Diffuse Scleroderma are looking for participants at sites in California.

Cities in California

A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis

  • UCLA, Los Angeles
  • Hoag Hospital, Newport Beach
RecruitingPhase 2
Ages 18 to 70 · All sexes · Updated Sep 28, 2026 · NCT06470048

EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

  • EncompaSSc site in La Jolla, CA, La Jolla
  • EncompaSSc site in Loma Linda, CA, Loma Linda
  • University of California Los Angeles Scleroderma Center, Los Angeles
  • and 2 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT07287670

A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

  • Loma Linda University Medical Center, Loma Linda
RecruitingPhase 1
Ages 18 to 74 · All sexes · Updated Sep 10, 2026 · NCT07085104

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

  • GSK Investigational Site, Los Angeles
  • GSK Investigational Site, Los Angeles
  • GSK Investigational Site, Los Angeles
  • and 1 more
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT05878717

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

  • UC San Diego Health, La Jolla
  • Stanford University Medical Center, Redwood City
RecruitingPhase 1
Ages 18 to 70 · All sexes · Updated Aug 28, 2026 · NCT06925542

Platform Clinical Study for Conquering Scleroderma

  • Keck School of Medicine at USC Medical Center, Los Angeles
  • Cedars-Sinai Medical Center, Los Angeles
  • Stanford University Medical Center, Palo Alto
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT06195072

A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

  • Nkarta Investigational Site, Orange
RecruitingPhase 1/2
Ages 18 to 75 · All sexes · Updated Aug 7, 2026 · NCT06733935

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

  • Artiva Investigational Site Chula Vista, Chula Vista
  • Artiva Investigational Site Covina, Covina
  • Artiva Investigational Site Los Alamitos, Los Alamitos
  • and 3 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 31, 2026 · NCT06991114

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.